- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about WSNAF
Recent news which mentions WSNAF
Psyched: Australia's Innovative Program, Congressional Amendments, Therapy Reimbursement And More
July 11, 2023
From Benzinga
Wesana Shareholders Vote For Psilocybin And CBD Therapy Asset Sales To Lucy Scientific
June 12, 2023
From Benzinga
Disney, Amgen, First Republic, Psychedelics: How One CEO's Universal Deal-Making Approach Shapes Industries
June 05, 2023
From Benzinga
EXCLUSIVE: Infrastructure Built For Healing: 'Consolidation And Legitimacy Are Crucial For Psychedelic Industry Growth'
April 13, 2023
From Benzinga
What To Expect From The Benzinga Psychedelics Capital Conference, The Must-Attend Event For This Emerging Industry
April 03, 2023
From Benzinga
High-Profile Highs: How Celebrity Advocacy Is Transforming Society's Views On Psychedelics And Cannabis
March 29, 2023
From Benzinga
From Benzinga
Lucy Scientific Shares Trading Higher On Asset Purchase Agreement Of Psychedelic Assets From Wesana Health
March 21, 2023
From Benzinga
From Benzinga
Wesana Sells Clinic Management Services Organization To Strengthen Assets
September 02, 2022
Tickers
WSNAF
From Benzinga
4 Psychedelics Companies Post Financial Results: Learn How Field Trip, Wesana, Braxia and Irwin Naturals Performed
August 30, 2022
From Benzinga
From Benzinga
Missed The Benzinga Psychedelics Capital Conference? Check Out Full Recording And Exclusive Coverage
April 25, 2022
From Benzinga
Daniel Carcillo Explains How Wesana Health Is Using Psychedelics To Treat Traumatic Brain Injury
April 20, 2022
From Benzinga
EXCLUSIVE: Catalysts To Watch For In The Psychedelic Space
April 19, 2022
From Benzinga
Wesana Health One Step Closer To Clinical Trials Of Psilocybin And CBD Based Treatment Of Brain Injury Related MDD
March 14, 2022
Tickers
WSNAF
From Benzinga
Psyched: Delix Raises $30M, New Ketamine Study For Alcohol Use Disorder, FDA Approves Ketamine Trial For ALS
January 18, 2022
From Benzinga
Psychedelics Biotech Companies Mark New Milestones In Drug Development Pipelines: Field Trip, Cybin and Wesana
January 11, 2022
From Benzinga
The Legacy Of Dr. Aaron Beck, Father Of Cognitive Therapy, Lives On In Psychedelic Medicine
November 04, 2021
From Benzinga
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
October 18, 2021
From Benzinga
From Benzinga
Psyched: First Active Psychedelics ETF Hits NYSE, Compass Dives Into Novel Molecules, Atai Subsidiary Launches Phase 2a Trial
September 20, 2021
From Benzinga
Can MDMA Treat Traumatic Brain Injury? $1.5 Million Are Being Committed To Finding Out
September 14, 2021
Tickers
WSNAF
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.